December, 05th | 15:03 - 15:06
Subretinal delivery of investigational abbv-rgx-314 as a gene therapy for neovascular age-related macular degeneration (namd): interim results of bilateral dosing from a fellow eye study
HO ALLEN
Full program
Add to calendar